BioMS Technology Corp. Report issue

For profit Phase 3
Founded: Edmonton Canada (1999)
Status: Defunct (2011)

Organization Overview

First Clinical Trial
2004
NCT00869726
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

dirucotide (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Chronic Progressive (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 3)

Neoplasm Metastasis (Phase 3)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1